Trials / Completed
CompletedNCT02081599
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
A Phase IV Study of Teneligliptin (MP-513) in Combination With Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin in combination with Insulin with an extension treatment for up to 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneli (Teneligliptin) | |
| DRUG | Placebo | |
| DRUG | Insulin |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2014-03-07
- Last updated
- 2026-01-02
- Results posted
- 2017-01-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02081599. Inclusion in this directory is not an endorsement.